Related Experiment Videos
Thalidomide effects in Behçet's syndrome and pustular vasculitis
Archives of Internal Medicine
|May 1, 1986
Summary
Pustular vasculitis, a new disease concept, showed dramatic clinical improvement with thalidomide therapy. This treatment may work by inhibiting immune complex-induced vasculitis, not by affecting neutrophil activity.
Area of Science:
- Immunology
- Dermatology
- Rheumatology
Background:
- Pustular vasculitis is a newly recognized disease concept.
- It potentially links Behçet's syndrome, bowel bypass, bowel-associated dermatosis-arthritis, and disseminated gonorrhea.
Purpose of the Study:
- To evaluate the therapeutic efficacy and safety of thalidomide for pustular vasculitis.
- To investigate the mechanism of action of thalidomide in this condition.
Main Methods:
- Thalidomide therapy was administered to five patients with significant morbidity.
- Sequential four-week "on" and "off" therapeutic cycles were used.
- In vivo testing for circulating immune complexes (CIC) after histamine injection was performed.
Main Results:
- Dramatic clinical benefit was observed in all patients who completed the thalidomide cycles.
- In three of four patients, in vivo testing for CIC converted from positive to negative during therapy.
- No significant effects were noted on neutrophil migration or adherence-associated glycoproteins.
Conclusions:
- Thalidomide is a clinically effective and safe therapy for pustular vasculitis when administered with rigid monitoring.
- The mechanism of action likely involves inhibition of CIC-induced vasculitis rather than effects on neutrophil-mediated cytotoxicity.